1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD20
  4. CD20 Inhibitor

CD20 Inhibitor

CD20 Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-P99033
    Mosunetuzumab
    Inhibitor 99.05%
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
  • HY-P9960
    Ocrelizumab
    Inhibitor
    Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS).
  • HY-P99538
    Ublituximab
    Inhibitor 98.42%
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects.
  • HY-P99776
    Plamotamab
    Inhibitor
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.
  • HY-P99483
    Blontuvetmab
    Inhibitor 99.08%
    Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma.
  • HY-P99952
    Ripertamab
    Inhibitor
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).
  • HY-P99326
    Tositumomab
    Inhibitor
    Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.
  • HY-P99855
    Divozilimab
    Inhibitor 99.63%
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.
  • HY-P99308
    Ocaratuzumab
    Inhibitor
    Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
  • HY-P99501
    Zuberitamab
    Inhibitor
    Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.